Accelrys Adds Middleware to Product Line, Builds Consulting Staff with Synomics Buy | GenomeWeb

Accelrys, the newly launched software subsidiary of Pharmacopeia, said it expects to gain additional integration capability and consulting manpower through last week’s acquisition of Synomics.

In the transaction, valued at approximately $4 million, Accelrys agreed to acquire all of the outstanding stock of Synomics, which is privately held.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.